Study provides clues for designing new anti-addiction medications

March 22, 2012
The structure of the kappa-opioid receptor with bound antagonist JDTic is shown resting in a poppy flower, the source of opium. Credit: Yekaterina Kadyshevskaya, PSI:Biology GPCR Network, The Scripps Research Institute.

Scientists are now one step closer to developing anti-addiction medications, thanks to new research that provides a better understanding of the properties of the only member of the opioid receptor family whose activation counteracts the rewarding effects of addictive drugs. The study was supported by the National Institute on Drug Abuse (NIDA), the National Institute of General Medical Sciences and the National Institute of Mental Health, all components of the National Institutes of Health.

“Drug abuse and addiction remain devastating public health challenges in the United States,” said NIDA Director Dr. Nora D. Volkow. “This research could aid in the development of effective medications for the treatment of drug addiction, particularly to stimulants like cocaine, for which there are no medications currently available. It may also be valuable for the development of safer pain medications.”

Unlike the other subtypes, the kappa opioid receptor (KOR) is not associated with the development of physical dependence or the abuse potential of opiate drugs (e.g., heroin, morphine). Therefore, medications that act at the KOR could have broad therapeutic potential for addressing , pain, as well as other mental disorders. The leading compound in this context is JDTic because its specific binding to the KOR has been shown to reduce relapse to cocaine seeking in animal models. JDTic is currently in clinical trials to assess its safety and tolerability in humans.

In this new study, produced a high resolution three-dimensional image of JDTic bound to the human KOR. By mapping all the points of contact between JDTic and the human KOR, researchers were able to see how the two fit together. The emerging picture reveals critical new information that helps explain why JDTic binds so tightly and specifically to this particular opioid receptor. This advance opens the door to the development of compounds targeting the KOR with improved therapeutic profiles, including that of non-addictive pain medications.

Explore further: Study solves structure of 'salvia receptor', reveals how salvinorin A interacts with it

More information: The study by Wu et al., can be found at: www.nature.com . For information on prescription drug abuse, go to: www.drugabuse.gov/drugs-abuse/ … cription-medications .

Related Stories

Study solves structure of 'salvia receptor', reveals how salvinorin A interacts with it

March 21, 2012
At the molecular level, drugs like salvinorin A (the active ingredient of the hallucinogenic plant Salvia divinorum) work by activating specific proteins, known as receptors, in the brain and body. Salvinorin A, the most ...

Suboxone is most effective in treating painkiller addiction

November 7, 2011
Individuals addicted to prescription painkillers are more likely to succeed in treatment with the aid of the medication buprenorphine-naloxone (Suboxone), report McLean Hospital and Harvard Medical School researchers in today's ...

Researchers identify possible new targets for treating pain in women

August 18, 2011
Women and men experience pain, particularly chronic pain, very differently. The ability of some opioids to relieve pain also differs between women and men. While it has been recognized since the mid-nineties that some narcotic ...

Smokers' genetic background impacts brain opioid receptors, smoking relapse

May 16, 2011
Nearly everyone who has tried to quit smoking says it's incredibly difficult, and the struggle is due in part to genetic factors. Now, a new study from the Raymond and Ruth Perelman School of Medicine at the University of ...

Recommended for you

Concern with potential rise in super-potent cannabis concentrates

July 21, 2017
University of Queensland researchers are concerned the recent legalisation of medicinal cannabis in Australia may give rise to super-potent cannabis concentrates with associated harmful effects.

Findings link aldosterone with alcohol use disorder

July 18, 2017
A new study led by scientists at the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health, demonstrates that aldosterone, a hormone produced in the adrenal glands, may contribute ...

Depression among young teens linked to cannabis use at 18

July 17, 2017
A study looking at the cumulative effects of depression in youth, found that young people with chronic or severe forms of depression were at elevated risk for developing a problem with cannabis in later adolescence.

Why does prenatal alcohol exposure increase the likelihood of addiction?

July 7, 2017
One of the many negative consequences when fetuses are exposed to alcohol in the womb is an increased risk for drug addiction later in life. Neuroscientists in the University at Buffalo Research Institute on Addictions are ...

Researchers say U.S. policies on drugs and addiction could use a dose of neuroscience

June 23, 2017
Tens of thousands of Americans die from drug overdoses every year – around 50,000 in 2015 – and the number has been steadily climbing for at least the last decade and a half, according to the National Institute on Drug ...

Study provides further support for genetic factors underlying addictions

June 13, 2017
Impairment of a particular gene raises increases susceptibility to opioid addiction liability as well as vulnerability to binge eating according to a new study.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.